Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Single-Center, Prospective Phase II Clinical Study of Proton Beam Intensity-Modulated Stereotactic Radiotherapy for Early-Stage Non-Small Cell Lung Cancer
Sponsor: Guangzhou Concord Cancer Center
Summary
This study included patients with early-stage lung cancer cT1-3N0M0, stage IA-IIB (AJCC eighth edition staging) who were inoperable or refused surgery. They were divided into peripheral type and central type according to the tumor location and received radical proton hypofractionated radiotherapy. The prescribed dose for patients with peripheral lung cancer is 48-60Gy(RBE)/4-6 fractions, and for patients with central lung cancer, the prescribed dose is 50-70Gy(RBE)/10-15 fractions. After treatment, follow-up visits will be conducted to observe short-term and long-term efficacy, adverse reactions and patient quality of life.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
65
Start Date
2026-02-20
Completion Date
2029-07-01
Last Updated
2026-02-17
Healthy Volunteers
No
Conditions
Interventions
Stereotactic Body Proton Therapy
They were divided into peripheral type and central type according to the tumor location and received radical proton hypofractionated radiotherapy. The prescribed dose for patients with peripheral lung cancer is 48-60Gy(RBE)/4-6 fractions, and for patients with central lung cancer, the prescribed dose is 50-70Gy(RBE)/10-15 fractions.
Locations (1)
Guangzhou Concord Cancer Center
Guangzhou, Guangdong, China